175 related articles for article (PubMed ID: 30408153)
1. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Bromberg JEC; Nierkens S; Jiwa NM; Minnema MC; Huibers MMH
Br J Haematol; 2019 Jun; 185(5):974-977. PubMed ID: 30408153
[No Abstract] [Full Text] [Related]
2. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
4. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
[TBL] [Abstract][Full Text] [Related]
5. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
6. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
9. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
[No Abstract] [Full Text] [Related]
10. Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases.
Iriyama C; Murate K; Iba S; Okamoto A; Goto N; Yamamoto H; Kato T; Mihara K; Miyama T; Hattori K; Kajiya R; Okamoto M; Mizutani Y; Yamada S; Tsukamoto T; Hirose Y; Mutoh T; Watanabe H; Tomita A
Cancer Med; 2023 Aug; 12(16):16972-16984. PubMed ID: 37501501
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis.
Rimelen V; Ahle G; Pencreach E; Zinniger N; Debliquis A; Zalmaï L; Harzallah I; Hurstel R; Alamome I; Lamy F; Voirin J; Drénou B
Acta Neuropathol Commun; 2019 Mar; 7(1):43. PubMed ID: 30885253
[No Abstract] [Full Text] [Related]
12. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
[No Abstract] [Full Text] [Related]
13. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.
Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Jiwa NM; Kuiper JJW; de Weger RA; Minnema MC; Huibers MMH
Crit Rev Oncol Hematol; 2018 Jul; 127():56-65. PubMed ID: 29891112
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone.
Hosoi H; Tanigawa I; Kosako H; Okamoto A; Iwamoto R; Koh J; Mori M; Hiroi T; Mushino T; Murata S; Tamura S; Murata SI; Tomita A; Sonoki T
Ann Hematol; 2022 Mar; 101(3):709-711. PubMed ID: 34216243
[No Abstract] [Full Text] [Related]
16. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
17. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
[TBL] [Abstract][Full Text] [Related]
18. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.
Poulain S; Boyle EM; Tricot S; Demarquette H; Doye E; Roumier C; Duthilleul P; Preudhomme C; Maurage CA; Morschhauser F
Br J Haematol; 2015 Jul; 170(2):285-7. PubMed ID: 25643939
[No Abstract] [Full Text] [Related]
19. Clinicopathologic correlates of
Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
[TBL] [Abstract][Full Text] [Related]
20. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
